Higher adherence to the EAT-lancet diet is associated with reduced risk of metabolic dysfunction-associated steatotic liver disease: a 5-year middle eastern cohort study [0.03%]
较高的EAT-Lancet饮食依从性与代谢功能异常相关脂肪肝病风险降低有关:一项为期五年的中东队列研究
Farzam Kamrani,Mobina Imannezhad,Elahe Etesami et al.
Farzam Kamrani et al.
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a rapidly increasing metabolic disorder worldwide. Sustainable dietary patterns such as the EAT-Lancet Diet (ELD), designed to promote both h...
Predictors of asymptomatic ketonemia in outpatients with diabetic kidney disease receiving SGLT-2 inhibitors: a cross-sectional study [0.03%]
钠-葡萄糖协同转运蛋白2抑制剂治疗的糖尿病肾病门诊患者的无症状性酮血症预测因素:横断面研究
Veysel Baran Tomar,Taha Enes Cetin,Asil Demirezen et al.
Veysel Baran Tomar et al.
Background: Sodium-glucose cotransporter-2 (SGLT-2) inhibitors are now foundational therapy for diabetic chronic kidney disease (CKD), yet their ketogenic metabolic effects in this population remain incompletely character...
Spiritual care for Latinx youth with type 1 diabetes (T1D) and their caregivers: qualitative analysis of focus groups [0.03%]
拉美裔1型糖尿病青年及其照顾者的灵性关怀:焦点小组的质性分析
Megan Visser,Jaquelin Flores Garcia,Rebecca Barber et al.
Megan Visser et al.
Background: Latinx youth with T1D experience systemic disparities in glycemic management and access to psychosocial support. Spiritual resources and needs may also impact diabetes distress and T1D management for youth and...
GLP-1 receptor agonists as multisystem therapies: from glycemic control to cardiorenal, neuroimmune, and metabolic disease [0.03%]
GLP-1受体激动剂作为多系统药物治疗:从血糖控制到心血管、肾脏、神经免疫和代谢疾病
Malek Zarei,Yasamin Hajiani
Malek Zarei
Background: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) were initially developed as incretin-based therapies for the management of type 2 diabetes mellitus. Over the past decade, robust clinical and mechanistic e...
Real-world comparative outcomes of atorvastatin, rosuvastatin, and lovastatin-niacin fixed-dose combination in metabolic dysfunction-associated steatotic liver disease: hepatic, metabolic, and economic perspectives [0.03%]
阿托伐他汀、罗苏伐他汀和洛伐他汀-烟酸固定剂量复方在代谢功能障碍相关非酒精性脂肪性肝病中的真实世界比较研究:肝脏、代谢及经济角度
Yi Tseng Tsai,Sriyani Padmalatha Konara Mudiyanselage,Yi-Jing Tsai et al.
Yi Tseng Tsai et al.
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a rising global health burden linked to dyslipidemia, metabolic syndrome, and hepatic inflammation. Statins are widely prescribed in MASLD, b...
Correction: Effects of intensive lifestyle modification incorporating calorie-carbohydrate restriction with or without time-restricted feeding on eating disorder psychopathology and diabetes-related distress in type 2 diabetes: a randomized controlled trial [0.03%]
纠正:在2型糖尿病中,纳入卡路里-碳水化合物限制(有或没有限时饮食)的强化生活方式改变对进食障碍心理病理和糖尿病相关痛苦的影响:一项随机对照试验
Saba Mohammadpour,Farzad Hadaegh,Farid Zayeri et al.
Saba Mohammadpour et al.
Published Erratum
Diabetology & metabolic syndrome. 2026 Jun 8;18(1):126. DOI:10.1186/s13098-026-02199-9 2026
Association of the CHG Index with the onset, progression, and prognosis of cardiovascular-kidney-metabolic syndrome: findings from two large prospective cohorts [0.03%]
CHG指数与心血管-肾脏-代谢综合征发病、进展和预后关联性的队列研究发现
Zehao Zhao,Yingxun Bai,Changsheng Ma et al.
Zehao Zhao et al.
Background: Cardiovascular-kidney-metabolic (CKM) syndrome represents a composite disease state driven by glucose and lipid metabolic dysregulation. The Cholesterol, High-density lipoprotein, and Glucose (CHG) index refle...
Upregulation of ADAM19 in dendritic cells is associated with immune features and lower C-peptide levels in type 1 diabetes mellitus [0.03%]
I型糖尿病中树突状细胞ADAM19的上调与免疫特征和较低的C肽水平相关
Lijun Chen,Changjian Yan,Chunling Huang et al.
Lijun Chen et al.
Background: Type 1 diabetes mellitus (T1DM) is a chronic metabolic disorder characterized by the autoimmune destruction of insulin-producing β-cells in the pancreas, leading to absolute insulin deficiency and persistent ...
Safety and metabolic effects of HTD1801 in type 2 diabetes and MASLD: a phase Ib randomized trial [0.03%]
HTD1801在2型糖尿病和MASLD患者中的安全性与代谢影响:一项II期随机试验
Jiajia Mai,Hong Zhang,Min Wu et al.
Jiajia Mai et al.
Background: HTD1801 is a novel compound composed of equal parts berberine (BBR) and ursodeoxycholic acid (UDCA). It functions as a gut-liver metabolic modulator with a unique mechanism of action that may offer therapeutic...
Development and temporal external validation of a high-specificity XGBoost rule-in model for diabetes in middle-aged and older Korean adults [0.03%]
开发并进行时间外部验证一种针对中老年韩国成人糖尿病高特异性的XGBoost筛选模型
Soo Myeong Kim,Jung Min Cho
Soo Myeong Kim
Early identification of diabetes in older adults is essential for preventing complications, yet many high‑risk individuals remain undetected in community settings. Using recent cycles of the nationally representative Korea National Health ...